ClinicalTrials.gg
CompletedNCT00480753Updated Dec 24, 2007

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

A Phase 2 interventional study of Nitroglycerin in Raynaud's Disease, sponsored by MediQuest Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-12-24.

Sponsored by MediQuest Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.

Planned enrollment
22nd of 33
15 · median 34
Started
2007
with 2 others
Phase 2
8 of 33
none open now
Registered
7th of 33
by date
Lead sponsor
8 of 33
MediQuest Therapeutics

Among the 33 studies in Raynaud Disease with a site in United States, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2007, is one of 8 in phase 2, and was the 7th registered.

Raynaud Disease

81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.

Browse Raynaud Disease studies →

Open to participants now

2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Raynaud Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also be monitored.

Read the detailed description

It is the intention of this protocol to study, in a controlled manner, the response of fingers of patients with Raynaud's phenomenon to two dosage strengths of a fast acting topical formulation of Nitroglycerin, MQX-503. Patients may have moderate to severe primary Raynaud's phenomenon or Raynaud's phenomenon secondary to autoimmune diseases such as scleroderma.

Quantitative changes in blood flow in the fingers of the non-dominant hand will be measured after the clinical induction of constriction of blood vessels by exposure to local cold temperatures. Secondarily, the quantitative reduction in skin temperature recovery time and symptoms of pain, tingling and numbness associated with Raynaud's phenomenon will be evaluated using a patient hand symptom analog assessment score. The frequency and severity of adverse events associated with MQX-503 will be assessed.

03

Conditions studied

  • Raynaud's Disease

Browse trials for

Keywords

  • Raynaud's phenomenon
  • Raynaud's Disease
  • Raynaud's disease secondary to scleroderma
  • Raynaud's phenomenon secondary to autoimmune disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Raynaud's phenomenon
  • Patients who are willing to discontinue any current therapies for Raynaud's phenomenon

Exclusion criteria

Exclusion Criteria:

  • The use of any medication containing nitroglycerin or known to interact with nitroglycerin
  • Patients with a history of migraine or other severe headaches
  • Open skin lesions or skin conditions in the area where medication is to be applied
  • Pregnant or nursing women or those wishing to become pregnant.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
15 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in blood flow in the fingers of the non-dominant hand after the induction of constriction of blood vessels by exposure to local cold temperatures.

    Time frame: 130 minutes

Secondary outcomes

  1. Reduction in skin temperature recovery time and symptoms in the fingers of the non-dominant hand after the induction of constriction of blood vessels by exposure to local cold temperatures.

    Time frame: 130 minutes

  2. Frequency and severity of adverse events

    Time frame: 2 weeks

07

Study locations

1 site
  • The Center for Rheumatology
    Albany, New York 12206, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2007
First posted
May 31, 2007
Start
May 2007
CompletionActual
Aug 2007
Last update
Dec 24, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00480753
Lead sponsor
MediQuest Therapeutics
First posted
May 31, 2007
Start date
May 2007
Completion
Aug 2007
Last update
Dec 24, 2007

Study contacts

Lee Shapiro, MD
principal investigator · The Center for Rheumatology
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion